Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade) [Seeking Alpha]
Spherix Global Insights Finds Benlysta Exposure Expanding and Rheumatologists Increasingly Turning to Lupkynis in Lupus Nephritis [Yahoo! Finance]
Should Aurinia's Surging 2025 Earnings and Upbeat 2026 Outlook Require Action From Aurinia (AUPH) Investors? [Yahoo! Finance]
Aurinia Pharmaceuticals (AUPH) Reports Financial Results for Three and Twelve Months Ended December 31, 2025 [Yahoo! Finance]
Aurinia Pharmaceuticals Q4 Earnings Call Highlights [Yahoo! Finance]